tiprankstipranks
XBiotech (XBIT)
NASDAQ:XBIT

XBiotech (XBIT) Stock Price & Analysis

319 Followers

XBIT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.05 - $8.18
Previous Close$7.99
Volume70.06K
Average Volume (3M)48.16K
Market Cap
$243.19M
Enterprise Value$43.17M
Total Cash (Recent Filing)$200.02M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-9.9
Beta1.23
May 09, 2019
EPS EstimateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding30,450,881
10 Day Avg. Volume80,291
30 Day Avg. Volume48,160
Standard Deviation0.20
R-Squared0.15
Alpha-0.00001
Financial Highlights & Ratios
Price to Book (P/B)1.11
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-17.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

42.17%4.15%4.09%49.60%
42.17%
Insiders
4.09% Other Institutional Investors
49.60% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

XBIT FAQ

What was XBiotech’s price range in the past 12 months?
XBiotech lowest stock price was $3.05 and its highest was $8.18 in the past 12 months.
    What is XBiotech’s market cap?
    Currently, no data Available
    When is XBiotech’s upcoming earnings report date?
    XBiotech’s upcoming earnings report date is May 09, 2019 which is 1807 days ago.
      How were XBiotech’s earnings last quarter?
      XBiotech released its earnings results on Mar 14, 2019. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.17.
        Is XBiotech overvalued?
        According to Wall Street analysts XBiotech’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does XBiotech pay dividends?
          XBiotech pays a Notavailable dividend of $2.5 which represents an annual dividend yield of N/A. See more information on XBiotech dividends here
            What is XBiotech’s EPS estimate?
            XBiotech’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does XBiotech have?
            XBiotech has 30,436,964 shares outstanding.
              What happened to XBiotech’s price movement after its last earnings report?
              XBiotech reported an EPS of -$0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
                Which hedge fund is a major shareholder of XBiotech?
                Among the largest hedge funds holding XBiotech’s share is Caxton Associates LP. It holds XBiotech’s shares valued at N/A.
                  ---

                  XBiotech Stock Smart Score

                  Company Description

                  XBiotech

                  XBiotech, Inc. is a biopharmaceutical company, which engages in development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. Its product pipeline include oncology, infectious diseases, dermatology, and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.
                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Advaxis
                  Fate Therapeutics
                  Kura Oncology
                  MacroGenics
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis